| scholarly article | Q13442814 |
| P2093 | author name string | D K Armstrong | |
| R E Bristow | |||
| R L Giuntoli | |||
| T P Diaz-Montes | |||
| P2860 | cites work | Cancer statistics, 2010 | Q27860525 |
| Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the G | Q33335882 | ||
| Gemcitabine reverses cisplatin resistance: demonstration of activity in platinum- and multidrug-resistant ovarian and peritoneal carcinoma | Q33345862 | ||
| Intraperitoneal cisplatin with intraperitoneal gemcitabine in patients with epithelial ovarian cancer: results of a phase I/II Trial | Q33360710 | ||
| Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103. | Q33490795 | ||
| Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study | Q33501657 | ||
| Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel | Q33503973 | ||
| Docetaxel: an active new drug for treatment of advanced epithelial ovarian cancer | Q40684894 | ||
| The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma | Q41711733 | ||
| Phase I trial of intraperitoneal gemcitabine in the treatment of advanced malignancies primarily confined to the peritoneal cavity. | Q46466258 | ||
| Intraperitoneal carboplatin infusion may be a pharmacologically more reasonable route than intravenous administration as a systemic chemotherapy. A comparative pharmacokinetic analysis of platinum using a new mathematical model after intraperitoneal | Q46646219 | ||
| Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. | Q50512108 | ||
| Intraperitoneal cisplatin and paclitaxel in ovarian cancer. | Q53263238 | ||
| Activity of Gemcitabine in Patients with Advanced Ovarian Cancer: Responses Seen Following Platinum and Paclitaxel | Q57265736 | ||
| Re-treatment of patients with recurrent epithelial ovarian cancer with cisplatin-based chemotherapy | Q69582605 | ||
| Oral etoposide is active against platinum-resistant epithelial ovarian cancer | Q72681506 | ||
| P433 | issue | 3 | |
| P921 | main subject | ovarian cancer | Q172341 |
| P304 | page(s) | 163-167 | |
| P577 | publication date | 2011-06-01 | |
| P1433 | published in | Journal of Chemotherapy | Q15754073 |
| P1476 | title | Feasibility of intravenous gemcitabine and an intraperitoneal platinum agent in the treatment of ovarian cancer | |
| P478 | volume | 23 |
Search more.